Cognito TX
2 known investors
Cognito Therapeutics develops Spectris, a non-invasive sensory stimulation technology platform to treat neurodegenerative diseases including Alzheimer's by improving cognitive performance. The company serves patients with neurodegenerative conditions and aims to transform disease management through clinical-to-commercial pathways in the neurological therapeutics sector.
Founders & leadership
CH
Christian HowellCEO
RK
Ralph KernChief Medical Officer
SW
Steve WorthyChief Business & Financial Officer
RZ
Robbert ZusterzeelChief Clinical & Regulatory Officer
TF
Thomas FaganEVP, Neurodegenerative Portfolio